Foto del docente

Elisabetta Poluzzi

Professoressa associata

Dipartimento di Scienze Mediche e Chirurgiche

Settore scientifico disciplinare: BIO/14 FARMACOLOGIA

Pubblicazioni

Baldin E.; Zenesini C.; Antonazzo I.C.; Bartolomei I.; Caniatti L.; Costa M.; Curti E.; Ferraro D.; Foschi M.; Granella F.; Guareschi A.; Immovilli P.; Lugaresi A.; Malagu S.; Mancinelli L.; Montepietra S.; Mussuto V.; Neri W.; Pasquinelli M.; Pellegrino L.; Pesci I.; Poluzzi E.; Pugliatti M.; Ravasio A.; Riise T.; Salvi F.; Santangelo M.; Sireci F.; Sola P.; Strumia S.; Tsantes E.; Vignatelli L.; Vitetta F.; Viti B.; D'Alessandro R., Antibiotic Use and Risk of Multiple Sclerosis: A Nested Case-Control Study in Emilia-Romagna Region, Italy, «NEUROEPIDEMIOLOGY», 2021, 55, pp. 224 - 231 [articolo]

Gatti M.; Rinaldi M.; Ferraro G.; Toschi A.; Caroccia N.; Arbizzani F.; Raschi E.; Poluzzi E.; Pea F.; Viale P.; Giannella M., Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta-analysis, «MYCOSES», 2021, 64, pp. 1317 - 1327 [articolo]

Raschi E.; Fusaroli M.; Ardizzoni A.; Poluzzi E.; De Ponti F., Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment, «BREAST CANCER RESEARCH AND TREATMENT», 2021, 186, pp. 219 - 227 [articolo]

Gatti, Milo; Raschi, Emanuel; Moretti, Ugo; Ardizzoni, Andrea; Poluzzi, Elisabetta; Diemberger, Igor, Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase, «VACCINES», 2021, 9, pp. 1 - 13 [articolo]

Scarpone, M; Bergami, M; Cenko, E; Bugiardini, R; Poluzzi, E; Manfrini, O, Previous psychiatric disorders and antipsychotic drugs in COVID-19 patients: early findings on possible worse outcome, «EUROPEAN HEART JOURNAL», 2021, 42, pp. 2753 - 2753 [abstract]

Aiello V.; Fusaroli M.; Raschi E.; Palazzini M.; Hu L.; Barbuto S.; Poluzzi E.; Capelli I., Pulmonary Embolism in a Patient With ADPKD Treated With Tolvaptan: From the Clinical Experience to the Analysis of the Food and Drug Administration Adverse Event Reporting System Registry, «KIDNEY INTERNATIONAL REPORTS», 2021, 6, pp. 2472-2477 - 2477 [articolo]

Raschi E.; Fadini G.P.; Diemberger I.; Poluzzi E.; De Ponti F., SGLT2 inhibitors for heart failure with reduced ejection fraction: a real EMPEROR?, «EXPERT OPINION ON PHARMACOTHERAPY», 2021, 22, pp. 647 - 650 [articolo]

Raschi E.; Caraceni P.; Poluzzi E.; De Ponti F., Baricitinib, JAK inhibitors and liver injury: a cause for concern in COVID-19?, «EXPERT OPINION ON DRUG SAFETY», 2020, 19, pp. 1367 - 1369 [replica/breve intervento]

Capelli, Irene; Vitali, Francesca; Zappulo, Fulvia; Martini, Silvia; Donadei, Chiara; Cappuccilli, Maria; Leonardi, Luca; Girardi, Anna; Aiello, Valeria; Galletti, Silvia; Faldella, Giacomo; Poluzzi, Elisabetta; DE Ponti, Fabrizio; Gaetano, LA Manna, Biomarkers of Kidney Injury in Very-low-birth-weight Preterm Infants: Influence of Maternal and Neonatal Factors, «IN VIVO», 2020, 34, pp. 1333 - 1339 [articolo]

Frega G.; Palloni A.; Di Pasquale G.; Saccoccio G.; Rizzo A.; Poluzzi E.; Iannone P.; Brandi G., Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements, «FRONTIERS IN PHARMACOLOGY», 2020, 11, pp. 1 - 6 [articolo]Open Access

Raschi E.; Fusaroli M.; Diemberger I.; Poluzzi E., Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance, «DRUG SAFETY», 2020, 43, pp. 1191 - 1194 [articolo]

Raschi E.; Gatti M.; Gelsomino F.; Ardizzoni A.; Poluzzi E.; De Ponti F., Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance, «TARGETED ONCOLOGY», 2020, 15, pp. 449 - 466 [articolo]

Gatti M.; Poluzzi E.; De Ponti F.; Raschi E., Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis, «DRUG SAFETY», 2020, 43, pp. 1277 - 1285 [articolo]

Iommi M.; Rosa S.; Fusaroli M.; Rucci P.; Fantini M.P.; Poluzzi E., Modified-Chronic Disease Score (M-CDS): Predicting the individual risk of death using drug prescriptions, «PLOS ONE», 2020, 15, pp. 1 - 13 [articolo]

Antonazzo I.C.; Poluzzi E.; Forcesi E.; Salvo F.; Pariente A.; Marchesini G.; De Ponti F.; Raschi E., Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug–drug interactions through the FDA adverse event reporting system, «ACTA DIABETOLOGICA», 2020, 57, pp. 71 - 80 [articolo]